Biocryst Pharmaceuticals Inc. (BCRX) concluded trading on Thursday at a closing price of $7.12, with 2.42 million shares of worth about $17.25 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 39.61% during that period and on October 10, 2024 the price saw a loss of about -1.79%. Currently the company’s common shares owned by public are about 205.77M shares, out of which, 195.87M shares are available for trading.
Stock saw a price change of -4.04% in past 5 days and over the past one month there was a price change of -7.89%. Year-to-date (YTD), BCRX shares are showing a performance of 18.86% which increased to 11.25% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $4.03 but also hit the highest price of $8.88 during that period. The average intraday trading volume for Biocryst Pharmaceuticals Inc. shares is 2.16 million. The stock is currently trading -6.63% below its 20-day simple moving average (SMA20), while that difference is down -8.57% for SMA50 and it goes to 12.99% higher than SMA200.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Biocryst Pharmaceuticals Inc. (NASDAQ: BCRX) currently have 205.77M outstanding shares and institutions hold larger chunk of about 82.38% of that.
The stock has a current market capitalization of $1.47B and its 3Y-monthly beta is at 1.90. It has posted earnings per share of -$0.73 in the same period. It has Quick Ratio of 2.78. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for BCRX, volatility over the week remained 3.36% while standing at 3.30% over the month.
Analysts are in expectations that Biocryst Pharmaceuticals Inc. (BCRX) stock would likely to be making an EPS of -0.06 in the current quarter, while forecast for next quarter EPS is -0.07 and it is -0.17 for next year. For the current quarter EPS, analysts have given the company a lowest target -0.09 which is -0.03 at the higher side of the target for the same. When we compare those targets with actual EPS, we find that company posted an EPS of -0.19 in the same quarter a year ago. Stock’s fiscal year EPS is expected to rise by 65.10% while it is estimated to increase by 60.71% in next year. EPS is likely to grow at an annualized rate of 44.80% for next 5-years, compared to annual growth of -3.73% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by JP Morgan on November 20, 2023 offering an Overweight rating for the stock and assigned a target price of $10 to it. Coverage by RBC Capital Mkts stated Biocryst Pharmaceuticals Inc. (BCRX) stock as an Outperform in their note to investors on September 18, 2023, suggesting a price target of $10 for the stock. On August 04, 2023, Jefferies Upgrade their recommendations, while on July 13, 2023, BofA Securities Upgrade their ratings for the stock with a price target of $10. Stock get a Buy rating from Needham on February 22, 2023.
